SOCS1 and chronic myelogenous leukemia, BCR-ABL1 positive: As a result, SOCS1 expression may be a new and valuable marker for CML therapeutic follow-up, as well as a new therapeutic strategy for developing successful CML target therapies (Liu et al., 2003).